Stryker Corporation $SYK Stock: Talbot Financial LLC Increases Holdings

Talbot Financial LLC lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 22.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,125 shares of the medical technology company’s stock after acquiring an additional 13,179 shares during the quarter. Stryker accounts for 1.4% of Talbot Financial LLC’s portfolio, making the stock its 24th largest holding. Talbot Financial LLC’s holdings in Stryker were worth $19,587,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of SYK. Sankala Group LLC purchased a new stake in shares of Stryker during the fourth quarter valued at $26,000. Gables Capital Management Inc. acquired a new position in shares of Stryker in the 2nd quarter valued at $25,000. Kilter Group LLC acquired a new position in shares of Stryker in the 2nd quarter valued at $25,000. Cornerstone Financial Management LLC raised its holdings in Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after buying an additional 31 shares during the period. Finally, Highland Investment Advisors LLC acquired a new stake in Stryker during the 2nd quarter worth about $25,000. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Stryker news, Director Ronda Stryker sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on SYK. Raymond James Financial set a $370.00 price objective on shares of Stryker in a research note on Friday, July 31st. BTIG Research dropped their target price on shares of Stryker from $358.00 to $316.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. BMO Capital Markets restated an “outperform” rating and set a $317.00 price target on shares of Stryker in a report on Wednesday, September 9th. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Finally, Citizens Jmp reduced their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $369.00.

Stryker Stock Up 1.5%

NYSE:SYK traded up $4.48 during trading hours on Monday, hitting $299.14. 1,390,818 shares of the company’s stock traded hands, compared to its average volume of 2,444,056. The firm has a market cap of $114.74 billion, a P/E ratio of 31.00, a P/E/G ratio of 1.87 and a beta of 0.78. Stryker Corporation has a twelve month low of $267.00 and a twelve month high of $392.55. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock’s fifty day moving average price is $299.31 and its two-hundred day moving average price is $312.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 14.93 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.